Cancer: Belt and braces for BCR – ABL
Nature Reviews Drug Discovery 16, 312 (2017).
doi:10.1038/nrd.2017.79
Author: Megan Cully
The breakpoint cluster region–Abelson tyrosine kinase (BCR–ABL) fusion oncoprotein drives chronic myeloid leukaemia (CML). Although therapies targeting BCR–ABL — such as the pioneering compound imatinib — have dramatically improved patient outcomes, many patients need to remain on treatment, and drug resistance can emerge. Writing in
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Megan Cully Tags: Research Highlight Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Drugs & Pharmacology | Gleevec | Leukemia